Patcharee Komvilaisak

Patcharee Komvilaisak

Auto-generated profile, based on publicly available information

Patcharee Komvilaisak

Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2022 in Transfusion
Verified
Journal Article
Closed access
NTNattiya Teawtrakul
Nattiya Teawtrakul
DSDuantida Songdej
Duantida Songdej
CHChattree Hantaweepant
Chattree Hantaweepant
ATAdisak Tantiworawit
Adisak Tantiworawit
SLSupanun Lauhasurayotin
Supanun Lauhasurayotin
RGRed Blood Cell Disorders Study Group
Red Blood Cell Disorders Study Group

30 October 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
DSDuantida Songdej
Duantida Songdej
NTNattiya Teawtrakul
Nattiya Teawtrakul
NLNapat Laoaroon
Napat Laoaroon
PKPatcharee Komvilaisak
Patcharee Komvilaisak
PSPornpun Sripornsawan
Pornpun Sripornsawan
RGRed Blood Cell Disorders Study Group
Red Blood Cell Disorders Study Group

24 July 2025 in Blood Advances
Verified
Journal Article
Open access
ASAkiko Shimamura
Akiko Shimamura
AMAlexey Maschan
Alexey Maschan
CBCarolyn Bennett
Carolyn Bennett
SSSujith Samarasinghe
Sujith Samarasinghe
JFJason E Farrar
Jason E Farrar
DWDavid A. Williams
David A. Williams
Severe aplastic anemia (SAA) is a rare, life-threatening disease with acquired pancytopenia and hypocellular bone marrow. ESCALATE evaluated eltrombopag in combination with immunosuppressive therapy (IST) in pediatric patients (aged 1 to <18 years) with relapsed/refractory (R/R) or treatment-naïve SAA. The eltrombopag starting dose was 25 mg/d for patients aged 1 to <6 years and 50 mg/d for patients aged 6 to <18 years; dose modifications (maximum dose, 150 mg/d) were allowed to achieve a target platelet count of 50 × 109/L to 200 × 109/L. Eltrombopag was administered with cyclosporine A, with or without horse antithymocyte globulin, for 26 weeks and could be extended if clinically beneficial. Fifty-one patients were treated (R/R SAA, n = 14; treatment-naïve SAA, n = 37). Data were analyzed overall and as 2 cohorts: R/R and treatment-naïve cohorts. The overall response rate (ORR; per North American Pediatric Aplastic Anemia Consortium criteria) at 26 weeks was 54.9% in both cohorts combined and 71.4% and 48.6% in the R/R and treatment-naïve cohorts, respectively; most responders had sustained responses after discontinuing eltrombopag. Among baseline transfusion-dependent patients, 66.7% and 76.7% achieved red blood cell and platelet transfusion independence, respectively, with rates of 70% and 80% for the R/R cohort and 65.6% and 75.8% for the treatment-naïve cohort, respectively. The most common treatment-related adverse events were abnormalities in liver function tests, including increased bilirubin (43.1%), alanine aminotransferase (37.3%), and aspartate aminotransferase (33.3%). Eltrombopag with IST showed a trend toward a favorable ORR in the R/R cohort, with no new safety signals. This trial was registered at www.clinicaltrials.gov as #NCT03025698.

23 November 2023 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
DSDuantida Songdej
Duantida Songdej
PSPacharapan Surapolchai
Pacharapan Surapolchai
PKPatcharee Komwilaisak
Patcharee Komwilaisak
PSPornpun Sripornsawan
Pornpun Sripornsawan
SLSupanun Lauhasurayotin
Supanun Lauhasurayotin
PCPIMLAK CHAROENKWAN
PIMLAK CHAROENKWAN

13 November 2024 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
PYPimpitcha Youthong
Pimpitcha Youthong
SPSamart Pakakasama
Samart Pakakasama
PKPatcharee Komvilaisak
Patcharee Komvilaisak
PRPiya Rujkijyanont
Piya Rujkijyanont
CCChane Choed-Amphai
Chane Choed-Amphai
DSDarintr Sosothikul
Darintr Sosothikul
Background: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare subtype of non-Hodgkin lymphoma associated with hemophagocytic lymphohistiocytosis (HLH)/HLH-like systemic illnesses and germline HAVCR2 mutations. Although previous studies suggested successful treatment of SPTCL with immunosuppressive therapy (IST) without chemotherapy, IST data in pediatric SPTCL remain scarce. To explore characteristics and therapeutic outcomes, comparing IST-based and chemotherapy-based regimens in pediatric SPTCL, in this retrospective cohort study, patients with SPTCL diagnosed at age ≤20 years during 2007-2023 were enrolled from 6 hematology/oncology centers in Thailand. HAVCR2 exon 2 sequencing was performed using DNA extracted from peripheral blood or bone marrow. Presence of HLH/HLH-like systemic illnesses, treatment outcomes, and adverse events (AEs) were reviewed and analyzed. Results: Of 22 patients with SPTCL (median age at diagnosis, 11.5 years [range, 6.0-19.0]; 63.6% males), 86.4% harbored germline HAVCR2 mutation, either homozygous (77.3%) or heterozygous (9.1%) p.Y82C variant, while 68.2% developed HLH/HLH-like systemic illnesses. Overall, 36.4% received IST as first-line treatment. Durable complete remission (CR) was achieved in 71.4% and 50.0% after first-line chemotherapy and IST, respectively (P=0.45); however, chemotherapy tended to increase any AEs compared to IST (57.1% vs. 12.5%; P=0.07). The most common AEs were hypertension (27.3%), febrile neutropenia (18.2%), and fungal infection (13.6%). Among the relapsed cases, 71.4% could reach CR after subsequent-line therapy. Fatality (4.5%) only occurred in the chemotherapy group. Conclusions: Pediatric SPTCL in Thailand frequently involves germline HAVCR2 mutations and/or HLH/HLH-like systemic illnesses. With comparable response and modest therapy-related toxicity, IST-based regimens may alternatively be considered as first-line treatment for pediatric SPTCL.

8 July 2025 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
NSNongnuch Sirachainan
Nongnuch Sirachainan
PKPatcharee Komvilaisak
Patcharee Komvilaisak
COCornelia Heleen Van Ommen
Cornelia Heleen Van Ommen
Shoshana Revel-VilkShoshana Revel-Vilk
Shoshana Revel-Vilk
SOShouichi Ohga
Shouichi Ohga
MRMadhvi Rajpurkar
Madhvi Rajpurkar
Purpose: Vitamin K deficiency bleeding (VKDB) can occur in neonates and infants due to low placental transfer and storage of VK. Although the incidence has decreased with global VK prophylaxis at birth, VKDB remains a concern. This study aimed to assess the recent magnitude, risk factors, and outcomes of VKDB and barriers/limitations to VK prophylaxis.Patients and Methods: From 2021 to 2023, a survey questionnaire was distributed to physicians managing VKDB or administering VK prophylaxis through various international and national societies. Responses were analyzed using a chi‐square test and unsupervised hierarchical clustering.Results: Among 685 respondents from 38 countries, 289 (42.1%) reported treating 1–5 VKDB cases annually. Key risk factors included the lack of VK at birth and liver disease. Hierarchical clustering of survey responses identified three groups with shared characteristics based on geographical location and country economic status: Cluster 1 consisted of high‐income countries in Europe and North America; Cluster 2 included upper‐ to middle‐income countries in Asia; and Cluster 3 comprised low‐ to lower‐middle‐income countries in Asia. In all clusters, the lack of VK prophylaxis at birth was the most common risk factor; however, liver disease was more highly reported in Cluster 2 when compared to the other clusters. The most frequent barriers to VK prophylaxis included parental refusal of intramuscular injections in high‐income countries and limited availability of VK in low‐ to lower‐middle‐income countries.Conclusions: Despite the implementation of VK prophylaxis, VKDB remains a global issue. Guidelines for prophylaxis in infants with liver disease should be established, and comprehensive education on VKDB complications for parents and communities is essential. The limited availability of VK in certain parts of the world should be further explored and addressed to improve the management of this preventable disease in infants.